|1.||Kurup, Ravi Kumar: 8 articles (11/2003 - 07/2002)|
|2.||Kurup, Parameswara Achutha: 8 articles (11/2003 - 07/2002)|
|3.||Borgquist, Signe: 6 articles (01/2015 - 01/2008)|
|4.||Jirström, Karin: 6 articles (01/2015 - 01/2008)|
|5.||Mo, Huanbiao: 6 articles (11/2013 - 07/2004)|
|6.||Vaziri, Nosratola D: 6 articles (01/2013 - 05/2002)|
|7.||Mammen, Andrew L: 5 articles (08/2015 - 11/2012)|
|8.||Porter, Todd D: 5 articles (12/2012 - 03/2005)|
|9.||Caruso, Maria Gabriella: 4 articles (06/2010 - 09/2005)|
|10.||Saito, Yasushi: 4 articles (04/2010 - 05/2002)|
07/01/1995 - "Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia."
01/01/2004 - "The results of the present study, obtained by one-step RT-PCR assay, demonstrated that both SOD1 and the metal-free form of enzyme (Apo SOD1) inhibit HMG-CoA reductase gene expression in hepatocarcinoma HepG2 cells, in normal human fibroblasts, and in fibroblasts of subjects affected by familiar hypercholesterolemia. "
12/01/2000 - "Several studies have shown cardiovascular benefit in treating hypercholesterolemia with HMG-CoA reductase inhibitor. "
04/01/1994 - "The aim of this study was to evaluate in patients with primary hypercholesterolemia the consequences of an effective of chronic treatment with inhibitor of HMG-CoA reductase on vascular responsiveness to cold pressure test. "
01/01/2015 - "HMG-CoA reductase inhibitory activity and phytocomponent investigation of Basella alba leaf extract as a treatment for hypercholesterolemia."
01/01/2000 - "The results indicate that the HMG-CoA reductase inhibitor lowered TC and LDL-C levels and was useful in the treatment of hypoestrogenic hyperlipidemia for periods of at least 6 months."
04/01/2010 - "This study was aimed to compare efficacy of medical therapy between HMG-CoA reductase inhibitor and non-HMG-CoA reductase inhibitor group to changing of bone mineral density and bone markers in the patients with hyperlipidemia. "
01/01/2015 - "However, supplementation with GOH counteracted the hyperlipidemia by inhibiting HMG CoA reductase and suppressing lipogenesis. "
12/01/2014 - "In the treatment of hyperlipidemia, the combined administration of TCMs and HMG-CoA reductase inhibitor in treating hyperlipidemia shows stable efficacy and less adverse reactions, and provides a new option for the combined application of drugs. "
09/01/2012 - "High-LMPP treatment significantly reduced the HMG-CoA reductase expression by 56.5% in the liver compared with hyperlipidemia model group. "
|3.||Coronary Artery Disease (Coronary Atherosclerosis)
10/01/2003 - "JELIS is a large clinical trial that will evaluate whether EPA can make an additional improvement in mortality and morbidity of coronary artery disease beyond that of HMG-CoA reductase inhibitor treatment."
12/01/2005 - "The aim of this study was to analyse non-invasively the regional effect of therapy with an HMG-CoA reductase inhibitor on myocardial blood flow in patients with coronary artery disease (CAD) with special reference to segments with initially substantially impaired vasodilation. "
12/01/1999 - "We conclude that patients with established coronary artery disease on HMG CoA reductase inhibitor therapy have better vascular endothelial function than similar patients without the medication. "
03/01/1994 - "Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. "
02/01/1993 - "Design features of a controlled clinical trial to assess the effect of an HMG CoA reductase inhibitor on the progression of coronary artery disease. "
01/01/2003 - "HMG-CoA reductase inhibitor has protective effects against stroke events in stroke-prone spontaneously hypertensive rats."
05/01/1998 - "HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data."
01/01/2014 - "Our data support the idea that HMG-CoA reductase inhibition promotes brain remodeling and plasticity far beyond the acute stroke phase, resulting in neurological recovery. "
01/01/2014 - "In view of these observations, we were interested whether HMG-CoA reductase inhibition in the post-acute stroke phase promotes neurological recovery, peri-lesional, and contralesional neuronal plasticity. "
08/01/1998 - "[HMG-CoA reductase inhibitor and risk of stroke]."
06/01/2013 - "RSV pretreatment was associated with more Treg accumulation, less inflammatory response, and myocardial injury, suggesting that such cardioprotection against IRI was partially mediated by Treg-negative modulation of inflammation response, probably through the HMG-CoA reductase pathway."
01/01/2007 - "The role of HMG-CoA reductase inhibition in endothelial dysfunction and inflammation."
08/01/2006 - "Additionally, the association of such sub-clinical inflammation with HMG-CoA reductase gene expression was evaluated. "
04/28/2006 - "The search terms "statin", "HMG-CoA reductase inhibitor", "pleiotropic effects", and "inflammation" were used. "
01/01/2003 - "In addition to the hypolipidaemic effect, other potentially important effects, such as improvement of endothelial function and reduction of LDL oxidation and vascular inflammation, have been associated with HMG-CoA reductase inhibitor therapy. "
|2.||3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA)
|3.||Coenzyme A (CoA)
|1.||Continuous Ambulatory Peritoneal Dialysis (CAPD)
|2.||Blood Component Removal (Apheresis)
|4.||Transplantation (Transplant Recipients)
|5.||Drug Therapy (Chemotherapy)